Strong points: there were several clear caveats, mostly from independent experts interviewed.
Weaker points: failure to evaluate the evidence, failure to put into appropriate context of other alternative treatments for which there is FAR more data and experience.
Experimental outcomes need to be presented in a framework that avoids generating unrealistic expectations. There are many men who are affected with benign prostatic hyperplasia, so the information presented needs to do a better job of providing them with accurate, balanced, complete information that can facilitate a truly informed shared decision-making encounter with their doctors.
There was no discussion of costs. Why not? You can let a researcher say it’s ready to be used in certain patients, yet you can’t estimate a cost?
While reporting that 66 out 67 patients in the study experienced ‘improvement’ in symptoms, it was not clear to readers what exactly was improved, the extent to which it was improved, and what the satisfaction level with the improvement was. There was not an adequate presentation about the benefits from this procedure.
The story did not report on any harms observed in the 67 men who took part in the study reported on.
The last line of the story indicated that the findings should be considered ‘preliminary’ and an early paragraph indicated that the study had not yet even been presented at the meeting. And, while the story did note that 9 months was insufficient time to measure outcomes, it did not explicity address the limitations of a small case-series (with no comparison group).
A story like this must do a better job of helping readers understand why not all studies are equal, why when a researcher says this is “ready to be used” that needs to be backed up by data, and how there is a far greater evidence base for many other approaches to BPH, including other so-called minimally invasive procedures, and including a watch-and-wait approach that many men are happy with – which was never mentioned.
The story did not engage in overt disease-mongering. It would have been helpful to know that BPH rarely causes problems that require medical attention, though it can result in symptoms that are bothersome for some men.
Clinicians with expertise in treating benign prostatic hyperplasia and without apparent ties to the study reported on were quoted in this story.
The story provided some insight about how this new minimally invasive treatment for benign prostatic hyperplasia compared with TURP. However it neglected to mention that there are number of surgical techniques and minimally invasive techniques available for which there is comparable effectiveness and fewer complications than TURP. And while the study authors claim the new procedure has value because it didn’t have the higher risk for the need for re-operation, the 9-month follow-up was too short to actually be able to lay claim to this benefit.
The oddest part of the story was the line that other minimally invasive treatments “are less effective and have a greater risk of a need for reoperation according to background materials that accompanied the study. (emphasis added) Does that mean according to marketing materials provided? What was that source of that material? What a silly, unsubstantiated, unsourced thing to include!
The story allowed the lead researcher to boast that prostatic artery emoblization was ‘ready to be used in certain patients’. But then it quickly countered that with “but other experts aren’t so sure.”
The story could have stated much more emphatically that it is a stretch to think that PAE would be utilized in this new population on the basis of a single, small scale study, presented as an oral presentation at a meeting. Given that the procedure is still experimental at this point, it is unlikely to be widely available.
And although the story noted that few physicians are ‘trained to perform the procedure’ it should have been explicit that this is currently not an option for most men.
Nonetheless, we’ll give the story a BARELY satisfactory on this criterion.
The story seemed to suggest that the procedure reported on was novel; it should have mentioned (as the competing WebMD story did) that it is already in use to treat other non-cancerous, hyperplastic conditions.
Does not appear to rely solely on a news release.
Systematic, Criteria-Driven
Monday at #ADA2021, an infectious disease epidemiologist, a journalist, and a researcher shared perspectives on communication of risk in the era of COVID-19: http://ow.ly/ROfR30rMeE7 @AstleyCM @garyschwitzer @berthahidalgo @ADA_DiabetesPro
Shoutouts to @susan_bewley @drkevinknopf @MichaelBaum11 in this call for more than fawning coverage from press releases for these kinds of stories.
Also, linked history inside goes back 5 years just on Grail apparently trying to become Holy Grail. https://twitter.com/garyschwitzer/status/1408849696416841731
Comments
Please note, comments are no longer published through this website. All previously made comments are still archived and available for viewing through select posts.
Our Comments Policy
But before leaving a comment, please review these notes about our policy.
You are responsible for any comments you leave on this site.
This site is primarily a forum for discussion about the quality (or lack thereof) in journalism or other media messages (advertising, marketing, public relations, medical journals, etc.) It is not intended to be a forum for definitive discussions about medicine or science.
We will delete comments that include personal attacks, unfounded allegations, unverified claims, product pitches, profanity or any from anyone who does not list a full name and a functioning email address. We will also end any thread of repetitive comments. We don”t give medical advice so we won”t respond to questions asking for it.
We don”t have sufficient staffing to contact each commenter who left such a message. If you have a question about why your comment was edited or removed, you can email us at feedback@healthnewsreview.org.
There has been a recent burst of attention to troubles with many comments left on science and science news/communication websites. Read “Online science comments: trolls, trash and treasure.”
The authors of the Retraction Watch comments policy urge commenters:
We”re also concerned about anonymous comments. We ask that all commenters leave their full name and provide an actual email address in case we feel we need to contact them. We may delete any comment left by someone who does not leave their name and a legitimate email address.
And, as noted, product pitches of any sort – pushing treatments, tests, products, procedures, physicians, medical centers, books, websites – are likely to be deleted. We don”t accept advertising on this site and are not going to give it away free.
The ability to leave comments expires after a certain period of time. So you may find that you’re unable to leave a comment on an article that is more than a few months old.
You might also like